Home    Back

Longeveron mesenchymal stem cells    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
211Hypoplastic left heart syndrome1

211. Hypoplastic left heart syndrome    [ 20 clinical trials,   28 drugs,   (DrugBank: 9 drugs),   5 drug target genes,   13 drug target pathways]
Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 20 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03525418
(ClinicalTrials.gov)		February 21, 201819/2/2018Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)HLHSBiological: Longeveron Mesenchymal Stem CellsLongeveron LLCNULLActive, not recruitingN/A1 YearAll30Phase 1;Phase 2United States